Intravenous to oral antibiotic switch therapy

Drugs of Today

Volumn 37, Issue 5, 2001, Pages 311-319

  Cunha, B A ^a  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFAZOLIN; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DOXYCYCLINE; ERYTHROMYCIN; FLUCONAZOLE; GATIFLOXACIN; ITRACONAZOLE; LEVOFLOXACIN; LINEZOLID; MACROLIDE; METRONIDAZOLE; MINOCYCLINE; MOXIFLOXACIN; PYRROLE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNINDEXED DRUG; VANCOMYCIN; VORICONAZOLE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG COST; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG TISSUE LEVEL; GASTROINTESTINAL SYMPTOM; HOSPITAL DISCHARGE; HUMAN; INFECTION; LENGTH OF STAY; LIVER TOXICITY; PATIENT COMPLIANCE; PHARMACODYNAMICS; PHLEBITIS; PHOTOSENSITIVITY DISORDER; REIMBURSEMENT; REVIEW; SEIZURE; SEPSIS;

EID: 0034938322     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2001.37.5.627953     Document Type: Review

References (29)

1. Cost considerations in oral antibiotic therapy
2. Antimicrobial switch therapy
3. Duration and route of antibiotic therapy in community-acquired pneumonia: Switch and step-down therapy
4. Intravenous to oral antimicrobial stepdown therapy: Improving the quality of care and reducing costs
5. IV-to-PO switch therapy of community-acquired pneumonia
6. Intravenous-to-oral antibiotic switch therapy. A cost effective approach
7. Antibiotic resistance
8. Antibiotic side effects
9. Effectiveness of oral antibiotic treatment in nursing home-acquired pneumonia
10. The utility of an in-hospital observation period after discontinuing intravenous antibiotics
11. Cefixime for switch therapy
12. Pharmaceutical, pharmacokinetic and other considerations for intravenous to oral stepdown therapy
13. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin
14. Sequential switch therapy for lower respiratory tract infections: A European perspective
15. Cost issues and considerations when choosing antimicrobial agents
16. Pharmacoeconomics of antimicrobial therapy
17. Cost-effectiveness comparison of sequential ofloxacin versus standard switch therapy
18. Pharmacokinetic and pharmacodynamic considerations in antibiotic selection, with particular attention to oral cephalosporins
19. Transitional antibiotic therapy
20. Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired Streptococcus pneumoniae pneumonia
21. Switch therapy with β-lactam/ β-lactamase inhibitors in patients with community-acquired pneumonia
22. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia
23. Early switch from intravenous antimicrobials to oral clarithromycin in the treatment of hospitalized patients with community-acquired pneumonia
24. Early switch from intravenous to oral antibiotics and early hospital discharge: A prospective observational study of 200 consecutive patients with community-acquired pneumonia
25. Pharmacokinetic and pharmacodynamic considerations for antimicrobial use
26. Early switch from intravenous to oral antibiotics: Guidelines and implementation in a large teaching hospital
27. A prospective randomized study of inpatient intravenous antibiotics for community-acquired pneumonia: The optimal duration of therapy
28. Sequential therapy with cefuroxime followed by cefuroxime axetil in community-acquired pneumonia
29. Transitional parenteral-to-oral therapy in community-acquired pneumonia